12 March 2021
Israel’s Ministry of Health, Pfizer and BioNTech announced that real-world evidence demonstrates lower incidence of Covid-19 disease among individuals fully vaccinated with the Pfizer/BioNTech’s Covid-19 vaccine (BNT162b2), highlighting the significant public health impact of Israel’s quick, nationwide immunisation programme. The latest analysis showed that two weeks after the second dose, the vaccine was 97% effective in preventing symptomatic disease, severe or critical disease, and death.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Danish Health Authority has announced that it will suspend the use of AstraZeneca/Oxford vaccine for the next 14 days because of concerns about blood clots. Meanwhile, the European Medicines Agency (EMA) is also currently investigating the link between the Covid-19 vaccine and severe blood clots. Two individuals are reported to have died of conditions related with blood clots soon after receiving the AstraZeneca/Oxford vaccine.
The European Commission (EC) has approved a conditional marketing authorisation (CMA) for Johnson & Johnson (J&J)’s single-dose Covid-19 vaccine in individuals aged 18 and older. Results from the Phase III ENSEMBLE study found the J&J Covid-19 vaccine was well tolerated and 67% effective in reducing symptomatic Covid-19 disease.
